• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes.

作者信息

Lee J-Y, Kim G, Kim S R, Lee Y-H, Lee B-W, Cha B-S, Kang E S

机构信息

Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul, South Korea; Severance Hospital, Seoul, South Korea; Graduate School, Yonsei University College of Medicine, Seoul, South Korea.

Department of Internal Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 03722 Seoul, South Korea; Severance Hospital, Seoul, South Korea; Graduate School, Yonsei University College of Medicine, Seoul, South Korea; Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, South Korea.

出版信息

Diabetes Metab. 2017 Apr;43(2):191-194. doi: 10.1016/j.diabet.2016.11.005. Epub 2017 Jan 11.

DOI:10.1016/j.diabet.2016.11.005
PMID:28089373
Abstract
摘要

相似文献

1
Clinical parameters affecting dapagliflozin response in patients with type 2 diabetes.影响2型糖尿病患者达格列净反应的临床参数。
Diabetes Metab. 2017 Apr;43(2):191-194. doi: 10.1016/j.diabet.2016.11.005. Epub 2017 Jan 11.
2
Predictors of the response of HbA1c and body weight after SGLT2 inhibition.SGLT2抑制后HbA1c和体重反应的预测因素。
Diabetes Metab. 2018 Mar;44(2):172-174. doi: 10.1016/j.diabet.2017.10.003. Epub 2017 Nov 8.
3
Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK.达格列净可改善英国二级保健糖尿病诊所患者的血糖控制和体重，随访 44 个月时观察到这一结果。
Diabetes Metab Syndr. 2020 May-Jun;14(3):237-239. doi: 10.1016/j.dsx.2020.03.007. Epub 2020 Mar 26.
4
Changes in Glycemic Control and Body Weight After Initiation of Dapagliflozin or Basal Insulin Supported Oral Therapy in Type 2 Diabetes: A Primary Care Database Study.达格列净或基础胰岛素支持的口服治疗起始后2型糖尿病患者血糖控制及体重的变化：一项初级保健数据库研究
J Diabetes Sci Technol. 2017 May;11(3):590-596. doi: 10.1177/1932296816688011. Epub 2017 Jan 4.
5
Effectiveness of dapagliflozin on vascular endothelial function and glycemic control in patients with early-stage type 2 diabetes mellitus: DEFENCE study.达格列净对早期 2 型糖尿病患者血管内皮功能和血糖控制的疗效：DEFENCE 研究。
Cardiovasc Diabetol. 2017 Jul 6;16(1):84. doi: 10.1186/s12933-017-0564-0.
6
The effects of intermittent use of the SGLT-2 inhibitor, dapagliflozin, in overweight patients with type 2 diabetes in Japan: a randomized, crossover, controlled clinical trial.日本超重2型糖尿病患者间歇性使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂达格列净的效果：一项随机、交叉、对照临床试验
Expert Opin Pharmacother. 2017 Jun;18(8):743-751. doi: 10.1080/14656566.2017.1317748. Epub 2017 Apr 21.
7
Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.三种降糖药物对 2 型糖尿病患者非酒精性脂肪肝影响的比较：一项随机、开放标签、三臂、阳性对照研究。
J Diabetes Investig. 2020 Nov;11(6):1612-1622. doi: 10.1111/jdi.13279. Epub 2020 May 26.
8
Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.达格列净对伴或不伴糖尿病的心力衰竭患者心力衰竭恶化和心血管死亡的影响。
JAMA. 2020 Apr 14;323(14):1353-1368. doi: 10.1001/jama.2020.1906.
9
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure.达格列净在2型糖尿病合并心力衰竭患者中的疗效与安全性。
J Diabetes Complications. 2017 Jul;31(7):1215-1221. doi: 10.1016/j.jdiacomp.2017.02.001. Epub 2017 Feb 10.
10
Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.达格列净增加 2 型糖尿病患者的瘦肉组织与总体重比值。
Nutr Diabetes. 2021 Jun 12;11(1):17. doi: 10.1038/s41387-021-00160-5.

引用本文的文献

1
Blood glucose levels and bodyweight change after dapagliflozin administration.达格列净给药后血糖水平和体重变化。
J Diabetes Investig. 2021 Sep;12(9):1594-1602. doi: 10.1111/jdi.13516. Epub 2021 Feb 28.
2
Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白 2 抑制剂治疗 2 型糖尿病。
Nat Rev Endocrinol. 2020 Oct;16(10):556-577. doi: 10.1038/s41574-020-0392-2. Epub 2020 Aug 27.
3
Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study.
四重口服疗法在2型糖尿病实际临床中的疗效：一项回顾性观察研究
Diabetes Ther. 2020 Sep;11(9):2029-2039. doi: 10.1007/s13300-020-00881-3. Epub 2020 Jul 21.
4
Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes.影响恩格列净治疗 2 型糖尿病患者疗效的临床参数。
PLoS One. 2019 Aug 1;14(8):e0220667. doi: 10.1371/journal.pone.0220667. eCollection 2019.
5
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors.钠-葡萄糖共转运蛋白 2 抑制剂治疗效果的预测因素及最佳联合治疗方案的考虑。
Diabetes Metab J. 2019 Apr;43(2):158-173. doi: 10.4093/dmj.2018.0057. Epub 2019 Jan 25.
6
Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea.达格列净应答者的特征：韩国一项纵向、前瞻性、全国性达格列净监测研究
Diabetes Ther. 2018 Aug;9(4):1689-1701. doi: 10.1007/s13300-018-0470-9. Epub 2018 Jul 11.